Salarius Pharmaceuticals (NASDAQ: SLRX) shares are trading higher Monday after the company announced a merger agreement with Decoy Therapeutics, a privately held biopharmaceutical company.
Upcoming MilestonesDuring the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug
Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025 in norovirus-infected subjectsBOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) — Cocrystal